reason report
consolid industri may lead increas margin
pressur pt
bottom line remain cautiou walgreen follow
announc op acquir wellcar wcg
op result transact creat anoth industri titan
pharmaci spend revenu view
addit scale leverag afford merger creat margin
pressur us pharmaci segment assum bp
gross margin pressur retail pharmaci spend
estim would drive unfavor ep impact
medacorp check indic inclus prefer
narrow network reduc retail rate bp would
impli gross margin pressur bp
unfavor ep impact may low
captur increment volum market gross margin continu
deterior y/i basi complic issu on-going
gener deflat far slower rate brand inflat possibl
rebat go away may lead signific declin brand
list price given numer headwind face remain cautiou
reduc pt forward estim reaffirm
impact cnc-wcg deal like creat even
margin pressur wednesday announc acquisit
wcg deal creat anoth industri titan annual
pharmaci spend revenu beneficiari
concern addit scale newco could lead
margin pressur estim could much
bp us pharmaci gm impli headwind
assum market share newco retail script us
pharmaci adj margin declin
trend appear like continu given industri
narrow network still preval competit volum
like continu us pharmaci market competit
sever larg player compet volum past year
experienc declin gross margin
pharmaci busi volum increas
time period indic give
price margin exchang volum data pharmaci
benefit manag institut pbmi show preval
narrow network increas rel believ
trend continu battl prefer
placement within pbm network would expect gross
margin pressur continu
net debt total capit
price-to-earnings lt ep growth
ep
year price history/av daili volume mil
compani inform svb leerink llc research
ep exclud acquisition-rel cost acquisition-rel amort non-recur item includ lifo adjust revenu billion
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
headwind suppli chain provid yet anoth challeng
analysi nadac data center medicar
medicaid servic show gener deflat continu trend
high-singl low-doubl digit rang y/i meanwhil brand
inflat continu moder though found nadac
best estim brand price trend believ data clearli
show declin inflat consist prior work show fewer
smaller price increas crucial januari period link
price gener declin rate increas brand slow
simpli fewer dollar spread across suppli chain
valuat deserv view reason valu
current trade discount five-year averag multipl
believ discount warrant given numer headwind
margin pressur compani face compar pharma suppli
chain comp appear trade roughli in-lin entir group
continu navig unfavor price reimburs trend
reduc estim reduc ep
estim respect lower pt
assum lower gross margin busi due mainli on-going
reimburs pressur gener brand price headwind
competit market like manag team
believ industri face on-going signific challeng
like abat time soon remain cautiou retail
largest global pharmaci led retail pharmaceut wholesal
organ world walgreen us drugstor chain largest pharmaci chain
us store count industri size improv purchas power brand-nam
recognit improv store traffic overal volum health plan self-insur
employ seek reduc medic cost via restrict network believ walgreen in-stor
clinic may provid attract altern plan walgreen nation presenc also
attract mani plan view provid larg corpor broad access
view gener launch wave next sever year posit impact
bottom line walgreen balanc reward custom loyalti program help lower print ad
cost bring individu market benefit recent work increas wba privat
brand product share mix well new front-end merchandis strategi
posit impact same-stor sale profit addit walgreen recent deal allianc
boot abc/op offer promis long-term synergi global
growth back lost share esrx network disput
although grow accept narrow network remain risk walgreen provid
health plan wide array servic includ infus specialti dispens lab servic
hospit partnership primari care servic case walgreen also earli
mover advantag purchas jv boot deal walgreen
pbm may advantag case make retail chain payer agnost
mani strength believ retail channel face signific challeng
includ increasingli competit environ seek creat
restrict prefer narrow network deal effort captur store traffic volum
medacorp specialist check indic retail rate reduc
case keep pressur retail gross margin
furthermor on-going gener launch believ wave
larg behind us becom increasingli difficult show gross margin expans retail
also believ transact posit busi stock howev
deterior lose share even though deal approv investor
sentiment stock name appear low lastli threat amazon entri
pharmaci servic space continu weigh stock believ retail
exposur sinc own pbm given risk
concern rate share market perform
on-going industri consolid headwind
continu industri consolid support cautiou view remain cautiou
walgreen given on-going industri consolid view recent announc
acquisit wellcar wcg op op increas competit
pressur pharma suppli chain like lead gross margin pressur
wba us pharmaci busi estim addit scale newco signific
given annual revenu pharmaci spend increment leverag
scale like use retail rate set process could lead
bp increment usa retail gross margin pressur command
highest us pharmaci market share base total prescript revenu larg
nationwid presenc support recent acquisit store howev
pharmaci market competit believ singl chain larg enough pbm
manag care plan need in-network either op op includ
innetwork believ pharmaci network would larg enough presenc
meet patient access requir chart see larg number
retail chain fill retail pharmaci network mean plan
scale use retail drive reimburs
figur highest pharmaci market share competit intens
meanwhil cnc-wcg deal creat anoth industri titan annual revenu
beneficiari live view increas scale enabl newco extract
addit valu agreement pharmaci retail channel includ
unclear exactli much margin pressur exert retail heighten
leverag medacorp channel check indic plan gener save rate
implement restrict narrow network assum declin revenu
chang cog unfavor impact gross margin would
view gross margin compress high tabl show
unfavor ep impact would given reduct usa retail gross
margin newco book busi cnc deal call wednesday compani
disclos total pharmaci spend assum flow
mail channel market share retail pharmaci spend
estim aggreg unfavor ep impact could unfavor ep
impact transact could well assum margin
degrad deal rang
race bottom like continu
pharmaci margin remain pressur remain concern race bottom
pharmaci reimburs continu industri consolid increas
pressur face us pharmaci market host firesid chat break-out session
walgreen cfo jame keho svp ir gerald gradwel director ir jay spitzer
global healthcar confer link overal discuss highlight
continu navig sever headwind manag explain pharmaci
busi continu face signific reimburs headwind specif manag
point recent cvs-aet ci-esrx merger continu preval narrow
network caus race bottom reimburs rate accord
cnc-wgc pharmaci spend spend mail spend mail channel spend retail channel spend retail channel us market share pharmaci revenu gm pressur cnc-wgc us pharmaci adj flow-through gross gross profit rate tax impact dilut walgreen boot allianc inc
continu use scale win narrow network contract expens
reimburs rate retail seem trade blow back forth term
volum captur win share prefer network deal appear like margin remain
pressur
margin show slight uptick believ long-term trend
unfavor margin pressur continu retail gross margin still declin y/i
basi believ season busi slightli higher volum
winter month due flu season patient work deduct y/i
basi margin still declin despit higher volum oper profit also
declin y/i basi retail despit higher volum
figur pharmaci margin volum
meanwhil wba us pharmaci volum also increas margin contract
data seem show even though captur volum
broader market volum come expens price result margin
continu deterior view battl volum expens overal price like
continu indefinit believ possibl gross margin channel
continu deterior long-term
figur wba us pharmaci margin volum
narrow network still use one driver margin pressur competit
volum use narrow network fall host roundtabl new york
includ two medacorp panel focus theme import distribut specialti
pharmaci pbm coverag link roundtabl heard kol believ
narrow network still common may exclud frequent due
linger market percept premium retail support kol claim narrow
network remain preval pharmaci benefit manag institut pbmi trend
drug benefit design show preval narrow network increas rel
continu use narrow restrict network industri consolid
believ pressur face retail pharmaci like continu larg integr player
seek util scale reduc cog
figur wba us pharmaci margin volum
pharmaci benefit manag institut trend drug benefit design report
continu gener deflat moder brand inflat keep pressur
addit reimburs margin headwind face us retail pharmaci busi
rest pharma suppli chain face continu headwind price trend
analysi nadac price data center medicar medicaid servic
nadac data produc survey retail commun pharmaci intend creat
nation benchmark reflect price paid retail commun pharmaci
acquir prescript over-the-count cover outpati drug result believ
better indic true price trend incorpor discount rebat
perfect account discount rebat addit analysi equal
weight pleas see thorough explan link see gener
deflat appear stabil sever pharma suppli chain compani discuss
gener deflat continu estim stabl high singl digit y/i declin gener
price still present signific headwind entir pharmaci suppli chain lower
dollar valu gener script harder make money lower price-point
svb leerink estim
well pharma suppli chain continu face headwind brand inflat
continu moder nadac data best measur actual rate
inflat trend inflat track nadac data clearli show inflat
continu moder rebat elimin list price actual declin y/i basi
reimburs headwind get wors
figur brand inflat continu weaken
svb leerink estim
wba valuat rel peer reason
view current reason valu rel pharma suppli chain peer howev
fundament unfavor believ stock price repres good entri
point time current trade ntm price-to-earnings ntm ev/ebitda
wba five year averag multipl believ valuat
reason given mani headwind face compani addit peer pharma
suppli chain trade similar discount shown tabl
figur pharma suppli chain valuat remain depress rel histori
factset
trade five-year ntm price-to-earnings ntm ev/ebitda multipl sinc
believ discount valuat remain appropri light numer headwind face
compani reaffirm market perform rate
figur wba discount averag warrant
next month expect share trade ep
would put stock price multipl reflect on-going reimburs
pressur minim accret continu headwind intern
busi believ posit win share becom extens
network vast array clinic capabl believ new manag team
take step reduc overal cost increas sale higher margin front-stor product
posit retail rate remain signific pressur brand gener price
also headwind becom aggress overal respons
market also overhang unlik abat time soon given challeng
concern rate share market perform
risk valuat
competit high retail pharmaci industri highli competit contract
pbm manufactur also competit walgreen compet chain
independ drug store well mail order prescript provid groceri store on-line
pharmaci pharmaceut vendor chang competit landscap impact
rx volum neg impact compani sale earn
macroeconom regulatori climat uncertainti continu econom slowdown
 would bode poorli sinc above-averag unemploy rate drive lower level
consum spend would decreas prescript drug util regulatori
environ also fair amount uncertainti time impact variou healthcar
reform provis could materi impact wba oper nation emphasi reduc
healthcar cost could also spawn reimburs pressur new way contain healthcar
cost devis implement
intern exposur execut risk walgreen merger allianc boot increas
exposur intern market increas currenc exposur regulatori risk
wba partnership uniqu approach contract distribut
compani fail execut vision accret could expect
season time cost adjust swing result front-end sale
prescript sale compon season sale also lumpi depend
holiday line calendar sever cold cough flu season
magnitud compani lifo provis also fluctuat given quarter depend
inventori level sale inflat also swing result contribut earn
miss beat
amazon entri amazon may seek disrupt pharmaci market enter
retail market buy build contract pbm news topic pose
headlin risk share amazon could formid competitor mail cash pay
incom statement model fiscal year end august mm
compani report svb leerink llc estim
compani report svb leerink llc estim
sale
revenu
revenu
gross profit sg spread bp
equiti earn ab
share allianc boot associ
sale acquisit adjust
revenu
revenu
net earn attr nci
revenu
total non-gaap adjust tax
revenu
revenu
equiti earn allianc boot
sale acquisit adjust
incom statement model fiscal year end august mm
revenu
revenu
revenu
revenu
adjust equiti earn
elimin unalloc
sale
compani report svb leerink llc estim
incom statement model fiscal year end august mm
sale
equiti earn allianc boot
share allianc boot associ
previous held equiti interest
tax earn equiti method invest
net incom attrib non-control interest
net incom attrib walgreen
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
loss sale busi
gain previous held equiti interest
increas decreas fair market valu warrant
partial releas capit loss valuat allow
compani report svb leerink llc estim
